Skysona (gene therapy) for cerebral adrenoleukodystrophy (CALD)
Customize your policy alerts
Sign up for all blue cross blue shield - tennessee policy alerts
Know when blue cross blue shield - tennessee releases new policies or updates existing guidance.
Monitor payer policy activity
Covers medical necessity criteria, prior authorization, documentation, exclusions, and monitoring requirements for use of Skysona in boys with early, active cerebral adrenoleukodystrophy (CALD) for BlueCross BlueShield of Tennessee members.
No material clinical or coverage changes in this revision.
Coverage Criteria for Skysona (CALD)
Initial authorization for CALD
Covered when ALL of the following are met:
[[chunk 8]]
[[chunk 8],[chunk 4]]
[[chunk 5],[chunk 2],[chunk 8]]
[[chunk 8]]
[[chunk 8],[chunk 2]]
[[chunk 8],[chunk 9]]
[[chunk 9]]
The following scenarios are excluded from coverage for Skysona: use to treat or prevent adrenal insufficiency; genetic variants consisting of full deletions of the ABCD1 transgene; and Cerebral Adrenoleukodystrophy (CALD) secondary to head trauma. Coverage will not be provided for members meeting any of these exclusion criteria.
Any use of Skysona beyond the FDA‑approved indication and recognized compendial uses is considered experimental/investigational and not medically necessary and therefore is not covered under this policy.
Laboratory and Code Thresholds
Provider Actions and Prior Authorization Requirements
Prior authorization required; 3-month one-time authorization
Prior authorization is required. When all coverage criteria are met, authorization of 3 months for a one-time administration may be granted.
HSCT eligibility and donor-unavailability required
Member must be eligible for hematopoietic stem cell transplant (HSCT) but unable to find a human leukocyte antigen (HLA)-matched donor; member must not have received a prior allogeneic HSCT or prior gene therapy.
Documentation required to initiate prior authorization
Submit chart notes, medical records, or laboratory results documenting elevated very long chain fatty acids (VLCFA) per the laboratory reference range and a pathogenic or likely pathogenic ABCD1 gene variant. Include baseline hematologic, hepatic, renal, and cardiac assessments, MRI central radiographic review (Loes score and gadolinium enhancement), and Neurologic Function Score as part of the prior authorization package.
- Elevated VLCFA values (lab reference range).
- Pathogenic or likely pathogenic ABCD1 variant (genetic testing).
- Baseline labs and assessments: ANC, platelets, hemoglobin, AST/ALT, total bilirubin, creatinine/CrCl or eGFR, LVEF.
- Central radiographic MRI review showing gadolinium enhancement and Loes score; Neurologic Function Score (≤1).
Triggers for denial and active exclusions
Coverage will not be provided for members with full deletions of the ABCD1 transgene, for use of Skysona to treat or prevent adrenal insufficiency, or for CALD secondary to head trauma. Additional denial risks include active infection, hematologic/hepatic/renal/cardiac compromise, or immediate family history of a familial cancer syndrome per the exclusions.
- Full deletions of the ABCD1 transgene are excluded.
- Use to treat or prevent adrenal insufficiency is excluded.
- CALD secondary to head trauma is excluded.
- Active bacterial, viral, fungal, or parasitic infection or abnormal labs/organ dysfunction can trigger denial.
Background
Skysona is an autologous hematopoietic stem cell gene therapy indicated to slow neurologic progression in boys aged 4–17 years with early, active cerebral adrenoleukodystrophy (CALD). Early, active disease is characterized by gadolinium enhancement on brain MRI, Loes scores between 0.5 and 9, and minimal clinical symptoms (Neurologic Function Score ≤ 1). Authorization is for a one‑time administration and prior authorization is required.
Key Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.